Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07844031
Active, not recruiting Observational

Coagulation Profiles in Conventional and Minimal Invasive Extracorporeal Circulation

NCT07844031 · tracked via the Priya Life Science Turkey tracker
Sponsor
Bursa Yuksek Ihtisas Training and Research Hospital
Phase
Observational
Started
2025-10-01
Last updated
2026-09-28

Condition(s) studied

Coagulation Changes During Coronary Artery Bypass Grafting

Investigational drug(s) / intervention(s)

Conventional extracorporeal circulationMinimally invasive extracorporeal circulation

Conventional extracorporeal circulation: Conventional extracorporeal circulation used during isolated coronary artery bypass grafting, as selected in routine clinical care.

Minimally invasive extracorporeal circulation: Minimally invasive extracorporeal circulation (MiECC) used during isolated coronary artery bypass grafting, as selected in routine clinical care.

Study summary

The aim of this study is to compare the effects of conventional and minimally invasive extracorporeal circulation (MiECC) techniques, which are routinely used in open-heart surgery, on coagulation parameters.

Eligibility

Sex
ALL
Min age
30 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Age 30 to 70 years. * Undergoing isolated coronary artery bypass grafting. * No known coagulopathy. * No diagnosed advanced renal or hepatic failure affecting the coagulation profile. Exclusion Criteria: * Emergency surgery. * Repeat cardiac surgery. * Valve replacement surgery. * Postoperative intra-aortic balloon pump use. * Need for surgical revision. * Advanced renal or hepatic failure. * Inherited hematologic disease.

Primary outcome measure(s)

  • Change in Fibrinogen Concentration From Preoperative Baseline to 24 Hours After Surgery — Preoperative baseline through 24 hours after surgery
    Fibrinogen concentration is measured before surgery, immediately after surgery, and at 6 and 24 hours after surgery. The change from preoperative baseline to 24 hours is compared between the conventional extracorporeal circulation and MiECC groups.

Trial sites (1)

FacilityCityRegionStatus
SBÜ Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi Bursa Turkey (Türkiye)

More Bursa Yuksek Ihtisas Training and Research Hospital trials in Turkey

EXORA Block vs Epidural Analgesia in Gynecological Surgery Active, not recruiting
vNOTES vs Laparoscopy: Respiratory Mechanics and Hemodynamics Starting soon
Effect of Minimally Invasive Extracorporeal Circulation on Optic Nerve Sheath Diameter and Stroke Incidence in Isolated Open Heart Surgery Active, not recruiting
Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study. Recruiting
Effect of Injection Duration of Fascial Plane Blocks on Block Success Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07844031 on ClinicalTrials.gov ↗ ← All trials in Turkey